Expertise in
24
conditions

Dr. Arkadiusz Dudek

Oncology
MN - Cancer
200 1st St SW, 
Rochester, MN 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
24
conditions
MN - Cancer
200 1st St SW, 
Rochester, MN 

Overview

Arkadiusz Dudek is an Oncologist in Rochester, Minnesota. Dr. Dudek is highly rated in 24 conditions, according to our data. His top areas of expertise are Lung Cancer, Melanoma, Renal Cell Carcinoma (RCC), and Pleuropulmonary Blastoma.

His clinical research consists of co-authoring 104 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Internal Medicine in MN

Hospital Affiliations

Mayo Clinic Hospital Rochester

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

MN - Cancer
200 1st St SW, Rochester, MN 55905

Additional Areas of Focus

Dr. Dudek has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: April 03, 2026
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: TAK-573, Pembrolizumab
Study Phase: Phase 1/Phase 2
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
Enrollment Status: Completed
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 3
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients With Advanced Solid Tumors
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: May 07, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer
A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer
Enrollment Status: Terminated
Publish Date: January 07, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer
Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: December 20, 2024
Intervention Type: Drug, Radiation
Study Drugs: Durvalumab, Chemotherapy
Study Phase: Phase 2
An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered With Encorafenib and Binimetinib in Patients With BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors
An Open-label Phase 1 Study to Evaluate Drug-Drug Interactions of Agents Co-Administered With Encorafenib and Binimetinib in Patients With BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 27, 2024
Intervention Type: Drug
Study Drugs: losartan, Dextromethorphan, Caffeine, Omeprazole, Midazolam, Rosuvastatin, Bupropion Immediate Release (IR), Encorafenib, Binimetinib, Modafinil
Study Phase: Phase 1
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Breast or Gynecologic Malignancies
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Drug
Study Drugs: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin, Nab-paclitaxel
Study Phase: Phase 1
Phase II Study of Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma:Hoosier Cancer Research Network LUN15-299
Phase II Study of Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma:Hoosier Cancer Research Network LUN15-299
Enrollment Status: Terminated
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ramucirumab
Study Phase: Phase 2
View 9 Less Clinical Trials

104 Total Publications

Impact of systemic imaging surveillance on survival from metastatic uveal melanoma.
Impact of systemic imaging surveillance on survival from metastatic uveal melanoma.
Journal: Melanoma research
Published: May 19, 2025
Similar Doctors
Expertise in
26
conditions
Dr. Stephen Ansell
Hematology | Oncology
Expertise in
26
conditions
Dr. Stephen Ansell
Hematology | Oncology

MN - Cancer

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-923-2592
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Ansell is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Ansell is highly rated in 26 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy.

Expertise in
13
conditions
Dr. Francis Buadi
Hematology | Oncology
Expertise in
13
conditions
Dr. Francis Buadi
Hematology | Oncology

MN - Cancer Transplant

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-910-0296
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Francis Buadi is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Buadi is highly rated in 13 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Primary Amyloidosis, Smoldering Multiple Myeloma, POEMS Syndrome, and Bone Marrow Transplant.

Prashant Kapoor
Expertise in
18
conditions
Dr. Prashant Kapoor
Hematology | Oncology
Expertise in
18
conditions
Dr. Prashant Kapoor
Hematology | Oncology

MN - Cancer Transplant

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-910-0296
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Prashant Kapoor is a Hematologist and an Oncologist in Rochester, Minnesota. Dr. Kapoor is highly rated in 18 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Waldenstrom Macroglobulinemia, Primary Amyloidosis, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Arkadiusz Dudek

How do I make an appointment with Dr. Arkadiusz Dudek?

You can book an appointment with Dr. Arkadiusz Dudek by calling their office at 507-512-1667. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Arkadiusz Dudek a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Arkadiusz Dudek is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Arkadiusz Dudek specialize in?

While Dr. Arkadiusz Dudek is a Oncology, they have specific expertise in Lung Cancer, Melanoma, and Renal Cell Carcinoma (RCC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Arkadiusz Dudek participate in research or clinical trials?

Yes. Dr. Arkadiusz Dudek has published 104 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Arkadiusz Dudek's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Arkadiusz Dudek accept my insurance?

Dr. Arkadiusz Dudek accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 507-512-1667 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dudek's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 77 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile